Keyword: Jounce Therapeutics

Jounce ends 2016 with $75M IPO offering

Six months after nabbing a potential $2.6 billion deal with Celgene, early-stage biotech Jounce has filed for a $75 million IPO that could serve as a broader litmus test for public offerings at the start of 2017.